

# Novavax Recognized by Washington Post as Top Workplace

June 17, 2016

(GLOBE NEWSWIRE via COMTEX) --GAITHERSBURG, Md., June 17, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), today announced that, for the third consecutive year, it has been recognized as a Top Workplace for 2016.

"At Novavax, we strive to create an environment where teamwork and collaboration thrive based on a culture that values and appreciates its employees," said Stanley C. Erck, President and CEO. "We have an incredibly motivated team that is driven to improve global health through the development of safe and effective vaccines. We are committed to making Novavax one of the Top Workplaces for years to come."

The Washington Post Top Workplaces are determined solely on employee feedback via an employee survey conducted by WorkplaceDynamics, LLP, a leading research firm on organizational health and employee engagement.

Jill Hoyt, Vice President, Human Resources, said, "We are especially proud to be recognized because our talented and engaged workforce is our most important asset. We believe that all good outcomes begin with happy employees and we are honored to receive this recognition from the Washington Post for the third consecutive year."

The Washington Post publishes the complete list of Top Workplaces on June 16, 2016. For more information about the Top Workplaces lists, please visit [www.topworkplaces.com](http://www.topworkplaces.com).

## About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, [novavax.com](http://novavax.com).

## Contact:

Novavax, Inc.

Barclay A. Phillips

SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.

Associate Director, Investor Relations

[ir@novavax.com](mailto:ir@novavax.com)

240-268-2000

Russo Partners, LLC

David Schull

Todd Davenport, Ph.D.

[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

[todd.davenport@russopartnersllc.com](mailto:todd.davenport@russopartnersllc.com)

212-845-4271

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novavax, Inc. via Globenewswire

HUG#2021062